CN1026463C - 可嚼胶囊的制备方法 - Google Patents

可嚼胶囊的制备方法 Download PDF

Info

Publication number
CN1026463C
CN1026463C CN86106150A CN86106150A CN1026463C CN 1026463 C CN1026463 C CN 1026463C CN 86106150 A CN86106150 A CN 86106150A CN 86106150 A CN86106150 A CN 86106150A CN 1026463 C CN1026463 C CN 1026463C
Authority
CN
China
Prior art keywords
carrier
composition
chewing
active
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN86106150A
Other languages
English (en)
Other versions
CN86106150A (zh
Inventor
布赖恩·埃尔伍德·琼斯
波拉·马里恩·奈特
马克·亚历山大·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Yanyeyi Europe Co ltd
Original Assignee
Yanyeyi Europe Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yanyeyi Europe Co ltd filed Critical Yanyeyi Europe Co ltd
Publication of CN86106150A publication Critical patent/CN86106150A/zh
Application granted granted Critical
Publication of CN1026463C publication Critical patent/CN1026463C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

一种含可咀嚼组合物的硬明胶胶囊，该组合物含有一种用于颊腔吸收或对颊腔具有活性的成分。

Description

本发明涉及关于胶囊，具体来说涉及明胶胶囊及其内含物。在很多情况下，能延长活性成分停留在口腔的时间是有益的。例如在使用消毒剂、喉痛药、感冒和咳嗽制剂和牙科组分时。通常当透过颊和舌下途径施用有力的药物以求迅速见效的情况下，亦要求延长活性成分停留在口腔的时间，以避免肠腔、肠壁或肝脏首先把药物排出。已有技术把每单位剂量的药物制成粉末或液体，放在软明胶胶囊内，咬穿后放出药物。但这些胶囊的缺点是胶囊的内含物在产生功效前已流下喉咙。
一个解决方法是加进一种不溶解、可咀嚼的组分，使软明胶胶囊可以咀嚼。但是，这方法仍不能避免食用者把内含物吞下，而把一个大的软明胶壳留在口腔内。
本发明提供了一个解决方法，这方法提供的单位剂量形式，其中所提供足够的活性成分可与颊腔的液体接触;并提供一种形式其有效成分能在颊腔内停留一段有效长的时间。
因此，这发明提供了含可咀嚼组分的硬明胶胶囊，上述组分包括：a）一种半固体组合物，这组合物包含着一种用作颊吸收的成分或与一种与无毒载体结合的对颊具有活性的成分和b）一种可咀嚼的增强剂，上述可咀嚼组合物在低于100℃的条件下处于液态。所述硬明胶胶囊最好含有一种可咀嚼组合物，这组合物包含a）一种用于颊吸收或对颊具有活性的成分，b）一种半固体无毒性载体和c）一种咀嚼增强剂，所述可咀嚼组合物在低于100℃的条件下处于液态。
载体可以包括一种或多种类脂体和水溶性原料，例如聚合物，天 然、合成或由一种或多种原料混合均可。载体的熔点最好在36℃至60℃之间。可自具有合适熔点和硬度的聚乙二醇（PEG）系列、由Gattefosse供应的Gelucire赋形剂系列或由Dynamit    Nobel如Witepsol和Softesan提供的赋形剂中选出适用的聚合物。PEG的分子量宜在200至10，000之间，在1000至2000之间更好，最好为1540。
可以使用其他原料作载体，单独使用或和上述的载体系统共同使用均可。这些原料包括动植物油和脂肪（可选择性地进行氢化）、烃类、带有12至18个碳原子的脂肪醇和脂肪酸、以及由它们生成的酯和盐等。
当活性成分是一种液体时，先用固体载体将其转变成一种半固体组合物。这载体亦可以是一种胶状载体，例如：胶状二氧化硅;或一种纤维素衍生物如甲基或乙基纤维素。其他适用的固体载体亦为本技术领域的技术员所熟知。
对颊具有活性的试剂可以是各种需用于颊腔的试剂，这种试剂或者具有局部作用，例如牙科中所用的活性试剂或用于作为治疗喉病痛或对颚和龈产生不适条件的药剂的情况;或者试图用于通过颊膜的吸收作用以提供迅速减轻发生在患有影响心脏疾病的病人的那些病症。
具体来说，本发明尤其作为施用于作用在心脏药物非常有用如硝苯啶（Nifedipine）、硝酸甘油（Nitroglycerin）、硝异山梨醇（Isosorbide    dinitrate）和普萘洛尔（Propranolol）。同时作为施用于止痛药中亦有用如丁丙诺啡（Buprenorphine）、喷他佐辛（Pentazocine）、苯佐辛（Phenzocine）、激素如催产素（Oxytocin）、雌激素（Oestrogens）和甲基睾丸素（Methyltestosterone）和镇静剂如三唑仓和氟西泮（flurazepam）。
利用本发明，可以把占直至95%（以重量计）的活性成渗入用于填充硬明胶胶囊壳的组合物中，若使用固体活性原料，活性成份最 好占直至20%。
胶囊内的组合物可含高达1000毫克的活性成分，而一般含1微克至250毫克。
本发明的组合物可以在口腔内停留颇长的时间，因此能让活性成分发挥最大的功效。把胶囊放进口内后即可咬嚼或使之在颊腔的唾液分秘中溶解。在以上任何一种情况，胶囊会迅速分散，轻易地把可嚼的物质留在口内。咬嚼可使物质迅速分散，若要求较长的吸收时间，则可把物质含在舌下。为了使组合物留在口中，必须把一咀嚼剂加入组合物中，这种咀嚼剂可以是一种或多种稳定剂或悬浮剂，该试剂包括树胶，例如：天然、合成和半合成植物胶如黄原胶、西黄蓍胶、金合欢树胶、胍尔豆胶或角豆荚胶;纤维衍生物如羧基甲基纤维素钠或羟基丙基甲基纤维素（HPMC），其他试剂如藻酸盐、明胶、聚烯吡酮，果胶和蜂蜡。较好的是黄原胶（参看马丁戴尔“Martindale”）。组合物的其他组分包括凝胶剂、香味剂和药物吸收促进剂。
在制备本发明的组合物时，最好的载体是选自聚乙二醇。许多医用药物的化合物可溶于PEG中，与唾液接触时能迅速地释放出来。
把活性成分和载体、咀嚼促进剂及其他需要的成分如凝胶剂或香味剂混合并把混合物搅拌，需要时可将混合物加热，以获得均匀的混合料。采用标准的方法把适当份量的混合料注入胶囊壳。咀嚼剂的作用在于使组合物可咀嚼，并能在口腔内停留一段充足的时间以便活性成分能发挥作用或被吸收。
已发现使组合物具有可接受的咀嚼和停留特性的稳定剂或悬浮剂在数量上有严格的限制。其用量可达至25%，但在反映本发明的特点的组合物中，黄原胶的含量按重量计从2%至15%较好，最好为约5%。
为了使胶囊更宜于咀嚼，可加进香味剂来掩盖活性材料或载体系统的味道。
最好的香料是薄荷，其用量在0.2%左右，因为薄荷最能掩盖试验中所用的载体的味道。香味能扩散到胶囊中，因此也能掩盖明胶的味道。
其他适合的香料包括香草精和橙。若使用柠檬果酸味，则最好加入柠檬酸以增进味道。
以下非制约性的例子能更详尽的说明本发明，胶囊内的可嚼组合物可用以下任何一种方法制备。基本的制备方法包括液化载体系统，然后和其他赋形剂混合。混合料是在熔化的状态下注入胶囊。
可使用以下方法：
1.在水槽上的烧杯内制备混合料，然后用注射器以人手操作，注入胶囊内。
2.在热板上的烧杯内制备混合料，然后用自动高压（Hibar）泵将混合料注入胶囊内。
3.使用Elanco    Rotop8胶囊填料机配合以Elanco    Model8胶囊填料机。
4.在一个用不锈钢密封的容器内制备混合料，并使用Harro    Hofliger    KFM填料机。
5.用Guisti混和容器制备混合料，然后采用Hofliger和Karg    GKF    1500L填料机把混合料注入胶囊内。
以上方法可用来制备各种尺寸的可嚼胶囊的批量。
实施例1
成分    重量    胶囊尺寸
普萘洛尔    10毫克    ＃4
黄原胶    10毫克
薄荷油    0.4毫克
PEG1540    100毫克
120.4毫克
实施例2
成分    重量    胶囊尺寸
硝苯啶    6毫克    ＃4
黄原胶    5毫克
橙味香料    0.3毫克
柠檬酸    0.4毫克
Gelucire    44/14    90毫克
101.7毫克
实施例3
成分    重量    胶囊尺寸
喷他佐辛    50毫克    ＃2
HPMC    30毫克
香草精    1毫克
PEG2000    200毫克
281毫克
实施例4
成分    重量    胶囊尺寸
夜樱草油    750毫克    ＃00
胶状二氧化硅    25毫克
黄原胶    25毫克
薄荷油    2毫克
802毫克
实施例5
成分    重量    胶囊尺寸
甲状腺素    25微克    ＃4
薄荷油    0.3毫克
西黄蓍胶    10毫克
PEG1000    140毫克
150.3毫克
实施例6
成分    重量    胶囊尺寸
乙酰水扬酸    300毫克    ＃0
Gelueire    35/10    300毫克
柠檬味料    1.2毫克
黄原胶    20毫克
621.2毫克
实施例7
成分    重量    胶囊尺寸
诺塞甾酮（Norethisterone）    5毫克    ＃1
PEG1000    300毫克
HPMC    15毫克
甘草味料    6毫克
326毫克
实施例8
成分    重量    胶囊尺寸
天仙子碱溴氢酸盐    300克    ＃1
PEG1540    300毫克
黄原胶    15毫克
樱桃味料    3毫克
318.3毫克

Claims (14)

1、一种制备硬明胶胶囊的方法，该方法包括往胶囊壁内引入一种可咀嚼组合物，该组合物包括a)由用作颊腔吸收或对颊腔具有活性的成分和一种无毒性载体所组成的半固体组合物和b)咀嚼促进剂，所述咀嚼组合物是在低于100℃温度下的熔化状态下注入胶囊的。
2、一种制备硬明胶胶囊的方法，该方法包括往明胶胶囊壁内引入一种可咀嚼组合物，该组合物包括a）一种用于颊腔吸收或对颊腔具有活性的成分，b）一种无毒性半固体载体和c）咀嚼促进剂，所述咀嚼组组合物是在低于100℃温度下的熔化状态下注入胶囊的。
3、按照权利要求1或2的方法，其中咀嚼促进剂是稳定剂或悬浮剂。
4、按照权利要求3的方法，其中咀嚼促进剂是树胶。
5、按照权利要求4的方法，其中树胶是黄原胶。
6、按照权利要求1或2的方法，其中载体是分子量为200-10，000的聚乙二醇。
7、按照权利要求1或2的方法，其中载体是分子量为400-4，000的聚乙二醇。
8、按照权利要求7的方法，其中聚乙二醇的分子量为1000-2000。
9、按照权利要求1或2的方法，其中组合物含有95%（重量）以下的活性成份。
10、按照权利要求9的方法，其中组合物含有20%-95%的固体活性成分。
11、按照权利要求1或2的方法，其中活性成分是一种作用于心脏的药物或止痛药。
12、按照权利要求1的方法，其中用于颊腔吸收或对颊腔具有活性的成分是液体，而载体是固体。
13、按照权利要求12的方法，其中载体是胶状二氧化硅或纤维素衍生物。
14、按照权利要求1或2的方法，其中组合物另外含有一种香味剂。
CN86106150A 1985-09-11 1986-09-08 可嚼胶囊的制备方法 Expired - Lifetime CN1026463C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858522453A GB8522453D0 (en) 1985-09-11 1985-09-11 Chewable capsules
GB8522453 1985-09-11

Publications (2)

Publication Number Publication Date
CN86106150A CN86106150A (zh) 1987-03-18
CN1026463C true CN1026463C (zh) 1994-11-09

Family

ID=10584991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN86106150A Expired - Lifetime CN1026463C (zh) 1985-09-11 1986-09-08 可嚼胶囊的制备方法

Country Status (22)

Country Link
US (1) US4755389A (zh)
EP (1) EP0215635B1 (zh)
JP (1) JPH089535B2 (zh)
KR (1) KR940002656B1 (zh)
CN (1) CN1026463C (zh)
AT (1) ATE69377T1 (zh)
AU (1) AU590792B2 (zh)
CA (1) CA1273295A (zh)
DE (1) DE3682467D1 (zh)
DK (1) DK174973B1 (zh)
EG (1) EG17919A (zh)
ES (1) ES2002302A6 (zh)
GB (1) GB8522453D0 (zh)
GR (1) GR862293B (zh)
HU (1) HU198837B (zh)
IE (1) IE59738B1 (zh)
IL (1) IL79973A (zh)
NZ (1) NZ217494A (zh)
PH (1) PH22155A (zh)
PT (1) PT83327B (zh)
RU (1) RU2018305C1 (zh)
ZA (1) ZA866849B (zh)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2611501B1 (fr) * 1987-03-04 1991-12-06 Corbiere Jerome Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention
GB8721455D0 (en) * 1987-09-11 1987-10-21 Lilly Industries Ltd Capsules
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135752A (en) * 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) * 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
DE4217932A1 (de) * 1992-05-30 1993-12-02 Hans Werner Dr Mander Verwendung eines lichtdurchlässigen, elastischen Hohlkörpers als Hilfsmittel bei der Aushärtung von lichthärtenden Zahnfüllungsmassen
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
GB9616672D0 (en) * 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
IN186245B (zh) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
DE69738333T2 (de) * 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US7163705B2 (en) 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US7935362B2 (en) 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
AU3885201A (en) 1999-09-20 2001-04-24 Mastercare Diet and weight control gum and sucker
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US7115288B2 (en) 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
IL158805A0 (en) * 2001-06-11 2004-05-12 Warner Lambert Co Breath protection microcapsules
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
FR2881321B1 (fr) 2005-02-03 2008-12-26 Axiss France Sas Soc Par Actio Additif alimentaire pour ruminants a base d'eugenol et de cinnamaldehyde
AU2006214166B2 (en) 2005-02-17 2011-09-29 Zoetis Belgium S.A. Transmucosal administration of drug compositions for treating and preventing disorders in animals
JP5256425B2 (ja) 2005-04-08 2013-08-07 リングアル コンセグナ ピーティーワイ エルティーディー 口腔送達システム
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007123955A2 (en) * 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
EP2124897A4 (en) * 2006-12-22 2012-05-09 Novadel Pharma Inc SPRAYING, ORAL, STABLE, SPRAY PREPARATIONS AND ASSOCIATED METHODS
US20080280947A1 (en) * 2007-05-10 2008-11-13 Blondino Frank E Anti-insomnia compositions and methods
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
DK2436383T3 (en) * 2009-05-29 2017-10-23 Morishita Jintan Co ORAL MEDICAL COMPOSITION AND ORAL MEDICAL Capsule WITH THE COMPOSITION CONCERNED
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US20120321703A1 (en) * 2011-06-16 2012-12-20 Daniel Kouri Capsule for oral pet medicine
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3427378A (en) * 1965-02-12 1969-02-11 American Cyanamid Co Sustained release encapsulated formula
NL7000180A (zh) * 1969-01-10 1970-07-14
SU432703A3 (zh) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
US4196189A (en) * 1977-03-19 1980-04-01 Blendax-Werke R. Schneider Dental and oral hygiene preparations
AU526184B2 (en) * 1978-06-27 1982-12-23 Scherer, R.P. Pty. Ltd. Appetite suppressant compositions
US4238475A (en) * 1979-08-01 1980-12-09 Life Savers Inc. Chewing cum capable of releasing finely divided water-insoluble materials therefrom
US4292304A (en) * 1980-09-30 1981-09-29 Barels Ronald R Oil based dentifrice
US4428927A (en) * 1981-05-11 1984-01-31 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
US4532126A (en) * 1982-05-07 1985-07-30 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
JPS5967218A (ja) * 1982-10-07 1984-04-16 Grelan Pharmaceut Co Ltd 軟質な口腔製剤
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
WO1985000516A1 (en) * 1983-08-01 1985-02-14 R. P. Scherer Corporation Sustained release method and product
WO1985003439A1 (en) * 1984-02-08 1985-08-15 R.P. Scherer Corporation Acetaminophen gelatin capsule providing rapid onset of therapeutic activity upon oral administration
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
GR862293B (en) 1987-01-02
KR870002839A (ko) 1987-04-13
EP0215635A2 (en) 1987-03-25
DE3682467D1 (de) 1992-02-27
PT83327A (en) 1986-10-01
EG17919A (en) 1991-06-30
PH22155A (en) 1988-06-01
IL79973A (en) 1990-06-10
AU590792B2 (en) 1989-11-16
RU2018305C1 (ru) 1994-08-30
PT83327B (pt) 1989-05-12
DK433886A (da) 1987-03-12
HU198837B (en) 1989-12-28
NZ217494A (en) 1989-03-29
IL79973A0 (en) 1986-12-31
JPS62116508A (ja) 1987-05-28
KR940002656B1 (ko) 1994-03-28
DK433886D0 (da) 1986-09-10
GB8522453D0 (en) 1985-10-16
US4755389A (en) 1988-07-05
IE862403L (en) 1987-03-11
AU6245586A (en) 1987-03-12
IE59738B1 (en) 1994-03-23
DK174973B1 (da) 2004-04-05
HUT43951A (en) 1988-01-28
CA1273295A (en) 1990-08-28
ES2002302A6 (es) 1988-08-01
EP0215635B1 (en) 1992-01-15
JPH089535B2 (ja) 1996-01-31
ZA866849B (en) 1987-11-25
ATE69377T1 (de) 1991-11-15
EP0215635A3 (en) 1988-01-13
CN86106150A (zh) 1987-03-18

Similar Documents

Publication Publication Date Title
CN1026463C (zh) 可嚼胶囊的制备方法
JP2565488B2 (ja) 活性剤の解放が制御された活性剤と可吸収性マトリックスからなる組成物
CN1091368C (zh) 含辅酶q10的药学组合物
JPH0579048B2 (zh)
JPS62281892A (ja) エストラジオ−ル−１７β−エステル
CZ345295A3 (en) Soft gelatin pharmaceutical dosing form
CN102215901A (zh) 用于治疗和/或预防疾病的装置和方法
CA1206414A (en) Waterless thixotropic composition
CN1279608A (zh) 含有溶解了帕罗西汀的制剂
CA2416566A1 (en) Depot formulation comprising ceftiofur and peroxidized natural oil
CN86100749A (zh) 制备改进的抗炎药剂的方法
JPH01149732A (ja) ソマトトロピン製剤
CN1720948A (zh) 红茴香滴丸及其制备方法
JP2006522804A (ja) 獣医学的使用のための経口投与剤形
CN1634061A (zh) 双酚伪麻药物制剂及其制备方法
CN1414847A (zh) 含吡喹酮的缓释抗蠕虫组合物
TWI250027B (en) Improved growth stimulant compositions
CN1191831C (zh) 复方阿替洛尔硝苯地平缓释制剂
CN1193759C (zh) 顺铂缓释体内植入药物及其制备方法
CN1302786C (zh) 一种治疗乳腺增生的中药软胶囊及其制备方法
CN115531439B (zh) 一种用于促进母猪发情的固体乳剂及其制备方法
CN1273115C (zh) 速效救心口崩片及制备方法
CN1989997A (zh) 一种咽炎清滴丸及其制备方法
CN1634073A (zh) 左氧氟沙星或其药用盐的口腔崩解片
CN1215880C (zh) 一种外用透皮贴剂的水溶性基质及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Holland

Applicant after: Yanyeyi Europe Co.,Ltd.

Address before: England, United Kingdom

Applicant before: Lilly Industries Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: LILLY INDUSTRIES LTD. (GB) KINGSCLERE ROAD, BASINGSTOKE, HAMPSHIRE RG21 2XA, ENG TO: SHIONOGI EUROPE LTD.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term